Main > A1. CORP. INDEX. A-Am No. 1 > Amgen Inc/P C2
This data is not available for free
Amgen Inc/P C2's subsections
2002. 03.15.2002. (Collaboration)
2002. 05.06.2002. (Lawsuit Revived)
2002. 05.13.2002. (CSF)
2002. 06.03.2002. (World No. 1)
2002. 07.29.2002. (Hematology)
2002. 08.27.2002. (Hematology)
2002. 09.23.2002. (Contract Mfg.)
2002. 09.23.2002. (Pat. Expiration)
2002. 10.14.2002. (Thrombolytic Ag)
2002. 10.28.2002. (Hematology)
2002. 11.04.2002. (Licensor of)
2002. 12.09.2002. (Arthritis)
2003. 01.27.2003. (Executive)
2003. 02.24.2003. (Ca ImBalance)
2003. 03.17.2003. (Arthritis)
2003. 03.17.2003. (Oncology)
2003. 05.26.2003. (Oncology)
2003. 05.31.2003. (Executive)
2003. 05.31.2003. (Oncology)
2003. 09.15.2003. (Diabetes)
2004. 01.12.2004. (Infinity Shares)
2004. 08.23.2004. (Tularik Pipeline
2006. 01.09.2006. License Agreement
2006. 01.30.2006. EU Expansion
2006. 01.30.2006. EU HeadQuarters
2006. 02.13.2006. Puerto Rico
2006. 04.24.2006. Alcon/Ophthalmo
2006. 10.30.2006. VP Chem. Research
2006. 10.30.2006. VP Licensing
2007. 06.04.2007. Sr VP R&D
2007. 08.20.2007. Director Oncolog
2007. 12.14.2007. Oncology >
2008. 01.24.2008. Endocrinology
2008. 02.04.2008. Takeda Pharma.
2008. 02.11.2008. CEO
2008. 03.05.2008. License Agreement
2008. 03.13.2008. Oncology>Anemia
2008. 03.17.2008. Etanercept
2008. 12.15.2008. Chem. Proc. R&D
2009. 04.27.2009. Diabetes
2009. 05.25.2009. CMO
2009. 05.26.2009. Cytokinetics
2009. 06.22.2009. VP Quality
2009. 07.20.2009. Reg. Affairs
2010. 08.11.2010. Onco.>Head & C.
2011. 01.06.2011. Xencor
2011. 03.04.2011. BioVex Acq.
2011. 03.30.2011. Onco>Lung C.
2011. 04.08.2011. BR Operations
2011. 04.11.2011. Onco>PI3K Inh.
2011. 07.05.2011. Endo>Osteoporosis
2011. 07.15.2011. Onco.>Bone Metast
2011. 07.15.2011. Teva Pharma
2011. 09.17.2011. Endo>Osteoporosis
2011. 09.19.2011. FDA Approval
2011. 10.13.2011. Director
2011. 10.19.2011. Exec VP Comm.
2011. 11.05.2011. Endo>Osteoporosis
2011. 11.05.2011. RA
2011. 11.22.2011. Patent
2011. 12.15.2011. CEO
2011. 12.19.2011. Watson Pharma.
2012. 01.26.2012. Corp. Acq.
2012. 02.14.2012. Sr. VP Global Dev
2012. 04.02. AstraZeneca
2012. 04.10. Kai Pharma Acq
2012. 04.26. Onco.>Prostate C.
2012. 05.16. Onco.>Gastric C.
2012. 06.08. Nephro.>CKD>HPT C
2012. 06.12. Acq. TK Co.
2012. 08.08. Onco.>Pancreas C.
2012. 09.11. Sr VP Corp Affair
2012. 09.20. Osteoporosis>D
2012. 10.12. Sr. VP & CCO
2012. 12.10. Corp. Acq.
2012. 12.13. BoD
2013. 01.08. Bind Biosciences
2013. 01.15. DSM
2013. 01.16. Cardio.>Anemia
2013. 01.16. SG Mfg. Facility
2013. 05.09. Onco.>Colon C. CN
2013. 05.29. & Astellas
2013. 06.12. CV.>Heart Failure
2013. 06.13. Benign Tumor>GCTB
2013. 07.09. CV.>Servier
2013. 08.25. Onyx Pharma. Acq.
2013. 09.24. CN>R&D Center
2013. 09.28. Onco.>Colon C.>P
2014. 01.01. Osteoporosis>R
2014. 01.09. Acting CFO
2014. 06.11. Psoriatic Arthritis
2014. 08.18. Nephro.>CKD>HPT V
2014. 11.04. Onco.>Ovarian C.
2014. 11.25. Derma.>Psoriasis
2014. 12.08. Onco.>HCM
2014. 12.22. LabCentral
2015. 01.05. Kite Pharma
2015. 04.06. Onco.>Colon C.>P+F
2015. 04.15. CV.>CHF>Ivabradine
2015. 07.24. Onco.>MM
2015. 09.14. NantPharma
2015. 09.15. CV..>HyperChol>FH
2015. 09.16. Acq. Dezima Pharma.
2015. 09.16. Xencor
2015. 12.18. Onco.>Melanoma
2016. 01.12. Onco.>ALL
2016. 07.11. CV..>HyperChol>FH
2016. 08.02. Onco.>Immuno.>Advaxis
2016. 09.01. Onco.>ALL>Ph(-)
2016. 09.01. Onco.>MM>BiTE>BI
2016. 09.23. 7 Inflammatory Dis.
2016. 11.11. Nephro.>CKD>HPT E
2017. 02.07. Nephro.>CKD>HPT E
2017. 06.12. USA>EPA>Award
2017. 06.29. Onco.>Colon C.
2017. 07.18. Array BioPharma
2017. 12.01. CV.>Evolocumab
2018. 10.01. Onco.>Multiple Myeloma
2018. 10.15. Inflammation
2019. 04.09. Osteoporosis R USA>OK
2019. 05.28. Acq. Nuevolution
2019. 07.18. Onco.>BioSimilars
2019. 08.26. Acq. Otezla®
2019. 10.08. Osteoporosis R CA>OK
2019. 10.31. Onco.>CN.>BeiGene
2019. 12.06. InflixiMAb BioSimilar
2019. 12.11. Osteoporosis R EU>OK
2020. 02.12. Otezla®>CA>OK
2020. 04.02. COVID-19 Treat.
2020. 08.20. Onco.>R/R MM
2021. 03.04. Acq. 5 Prime Therapeut
2021. 03.30. Acq Rodeo Therapeutics
2021. 05.28. Onco.>Lung C. USA>OK
2021. 06.23. Migraine JP>OK
2021. 07.27. Acq. TeneoBio
2021. 09.14. Onco.>Lung C. CA>OK
2021. 12.17. Pneumo.>Asthma>USA>OK
2022. 01.06. Generate Bio
2022. 01.09. Onco.>Lung C. EU>OK
2022. 08.04. Acq. ChemoCentryx
2022. 10.20. Acq. ChemoCentryx
2022. 12.12. Acq Horizon Therap.
2023. 02.02. USA FDA Approval
2023. 10.06. Acq Horizon Therap.
Amgen Dompé C2
Amgen Ventures C2
Patents
Web-Site
Z - OK
Amgen Inc/P C2's products
This section has no products